You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)擬不超1.2億元獲得上海創諾鹽酸厄洛替尼原料藥及片劑的商業化權利
格隆匯 11-07 18:22

格隆匯11月7日丨石藥集團(01093.HK)公佈,公司附屬公司石藥集團歐意藥業有限公司已與上海創諾製藥有限公司訂立協議,內容有關上海創諾開發的鹽酸厄洛替尼原料藥及片劑的產品轉讓。該產品已獲中國國家藥品監督管理局頒發藥品註冊批件,為國內該品種首家獲批的仿製藥,並已收錄到中國上市藥品目錄集中,視同通過一致性評價。

根據該協議,石藥歐意將獲得上海創諾轉讓該產品於中國(不包括香港、澳門及台灣)進行該產品有關的商業化及後續開發的獨家權利(包括完整所有權和知識產權),併成為該產品上市許可持有人。作為轉讓的代價,石藥歐意同意向上海創諾支付最多人民幣1.2億元的技術轉讓里程碑付款。石藥歐意亦同意根據該產品於該地區銷售額向上海創諾支付銷售提成,為期十年。

據悉,鹽酸厄洛替尼片為口服制劑,通過抑制腫瘤細胞配體依賴的HER-1/表皮生長因子受體(EGFR)的活性,達到抑制腫瘤細胞增殖的作用。獲批適應症為適用於EGFR基因具有敏感突變的局部晚期或轉移性非小細胞肺癌(NSCLC)患者的治療,包括一綫治療、維持治療,或既往接受過至少一次化療進展後的二綫及以上治療。鹽酸厄洛替尼片為《國家基本醫療保險、工傷保險和生育保險藥品目錄》醫保乙類品種。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account